Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort.
Xiaolei Shi(University of Maryland, Baltimore), Justin Hwang(University of Minnesota), Hannah E. Bergom(University of Minnesota), Nima Sharifi(Sylvester Comprehensive Cancer Center), Amol C. Shetty(University of Maryland, Baltimore), Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Elai Davicioni(Veracyte (United States)), Mohammed Alshalalfa(Veracyte (United States)), Krishnan R. Patel(National Institutes of Health), Ashley Ross(Northwestern University), Susan Halabi(Duke University), R. Jeffrey Karnes(Mayo Clinic), Phuoc T. Tran(The University of Texas MD Anderson Cancer Center), Emmanuel S. Antonarakis(University of Minnesota), Daniel Eidelberg Spratt(University Hospitals of Cleveland), Ella Boytim(University of Minnesota), Charles J. Ryan(University of Minnesota)
Cited by 0
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration
|Journal of Clinical Oncology|2020|676
Androgen Signaling in Prostate Cancer
|Cold Spring Harbor Perspectives in Medicine|2017|408